What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
In the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) received 9 analyst ratings, with 2 being bullish, 3 somewhat bullish, and 4 indifferent. The company has an average 12-month price target of $115.78, a decrease of 4.63% from the previous average price target of $121.40.
July 27, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biomarin Pharmaceutical received mixed analyst ratings, with a decrease in the average 12-month price target.
The mixed analyst ratings indicate uncertainty about the company's future performance. The decrease in the average 12-month price target could potentially impact the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100